LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

436.84 -3.22

Buy Sell

Overview

Share price change

24h

Current

Min

436.84

Max

436.84

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+59.74% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.4B 11B
Previous open	440.06
Previous close	436.84

News Sentiment

By Acuity

50%

141 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 lut 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 lut 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 lut 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 lut 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 lut 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 lut 2026, 23:21 UTC

Earnings

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 lut 2026, 23:20 UTC

Earnings

Nickel Industries 2025 Operating Profit US$126.4 Million

22 lut 2026, 23:19 UTC

Earnings

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 lut 2026, 23:19 UTC

Earnings

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 lut 2026, 23:18 UTC

Earnings

Nickel Industries Won't Pay a Final Dividend

22 lut 2026, 23:16 UTC

Earnings

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 lut 2026, 21:35 UTC

Earnings

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 lut 2026, 21:34 UTC

Earnings

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 lut 2026, 21:34 UTC

Earnings

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 lut 2026, 21:33 UTC

Earnings

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 lut 2026, 21:33 UTC

Earnings

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 lut 2026, 21:28 UTC

Earnings

Ampol Final Dividend A$0.60/Share

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Revenue A$31.37 Billion, Down 10%

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 lut 2026, 14:31 UTC

Acquisitions, Mergers, Takeovers

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 lut 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20 lut 2026, 23:12 UTC

Acquisitions, Mergers, Takeovers

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 lut 2026, 22:12 UTC

Earnings

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 lut 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 lut 2026, 21:23 UTC

Earnings

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 lut 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 lut 2026, 21:01 UTC

Acquisitions, Mergers, Takeovers

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 lut 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

59.74% upside

12 Months Forecast

Average 694.9 USD 59.74%

High 964 USD

Low 529 USD

Based on 11 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

141 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.